Xilio Therapeutics Files 8-K Report
Ticker: XLO · Form: 8-K · Filed: Sep 9, 2025 · CIK: 1840233
Sentiment: neutral
Topics: 8-K, SEC Filing, Corporate Update
Related Tickers: XLO
TL;DR
Xilio Therapeutics filed an 8-K, likely with financial updates or other corporate news.
AI Summary
On September 9, 2025, Xilio Therapeutics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates or disclosures related to the company's financial status and significant corporate events. No specific financial figures or new material events were detailed in the provided excerpt.
Why It Matters
This filing signals that Xilio Therapeutics is providing updated information to the SEC, which could include material events or financial updates relevant to investors.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report without immediate disclosure of negative events or significant financial changes.
Key Players & Entities
- Xilio Therapeutics, Inc. (company) — Registrant
- 0001558370-25-011949 (filing_id) — Accession Number
- September 9, 2025 (date) — Report Date
- 828 Winter Street, Suite 300, Waltham, Massachusetts 02451 (address) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing for Xilio Therapeutics?
The filing is primarily for "Other Events" and "Financial Statements and Exhibits," indicating updates or disclosures related to the company's financial status and significant corporate events.
What is the exact date of this 8-K report?
The report is dated September 9, 2025.
Where are Xilio Therapeutics' principal executive offices located?
The principal executive offices are located at 828 Winter Street, Suite 300, Waltham, Massachusetts 02451.
What is the Commission File Number for Xilio Therapeutics?
The Commission File Number is 001-40925.
What is the IRS Employer Identification Number for Xilio Therapeutics?
The IRS Employer Identification Number is 85-1623397.
Filing Stats: 918 words · 4 min read · ~3 pages · Grade level 13.1 · Accepted 2025-09-09 07:35:11
Key Financial Figures
- $0.0001 — ich registered Common stock, par value $0.0001 per share XLO Nasdaq Global Select
- $17.5 Million — odekin Alfa (XTX301) and Achievement of $17.5 Million Development Milestone On September 9,
- $17.5 million — nced solid tumors, the achievement of a $17.5 million development milestone under the Company
- $121.6 million — ompany had cash and cash equivalents of $121.6 million. Based on its current operating plans,
Filing Documents
- xlo-20250909x8k.htm (8-K) — 49KB
- xlo-20250909xex99d1.htm (EX-99.1) — 20KB
- 0001558370-25-011949.txt ( ) — 191KB
- xlo-20250909.xsd (EX-101.SCH) — 3KB
- xlo-20250909_lab.xml (EX-101.LAB) — 16KB
- xlo-20250909_pre.xml (EX-101.PRE) — 10KB
- xlo-20250909x8k_htm.xml (XML) — 5KB
01. Other Events
Item 8.01. Other Events. Initiation of Phase 2 Clinical Trial for Efarindodekin Alfa (XTX301) and Achievement of $17.5 Million Development Milestone On September 9, 2025, the Xilio Therapeutics, Inc. (the "Company") issued a press release announcing the initiation of patient dosing in Phase 2 of an ongoing Phase 1/2 clinical trial evaluating efarindodekin alfa (XTX301), a tumor-activated IL-12, as a monotherapy in patients with certain advanced solid tumors, the achievement of a $17.5 million development milestone under the Company's license agreement with Gilead Sciences, Inc. ("Gilead") and updated data from the ongoing Phase 1 trial for efarindodekin alfa. The full text of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information contained on, or accessible through, the websites referenced in the press release is not incorporated by reference into this Current Report on Form 8-K and should not be considered to be a part hereof. Updated Financial Guidance As of June 30, 2025, the Company had cash and cash equivalents of $121.6 million. Based on its current operating plans, the Company anticipates that its cash and cash equivalents as of June 30, 2025, together with the $17.5 million development milestone achieved under the license agreement with Gilead, will be sufficient to enable it to fund its operating expenses and capital expenditure requirements into the first quarter of 2027. The Company expects to receive the $17.5 million development milestone payment by the fourth quarter of 2025. Cautionary Note Regarding Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding the receipt of the development milestone payment and the Company's anticipated cash runway. The words "aim," "may," "will," "could," "
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release issued by Xilio Therapeutics, Inc. on September 9, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document and incorporated as Exhibit 101)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. XILIO THERAPEUTICS, INC. Date: September 9, 2025 By: /s/ Caroline Hensley Caroline Hensley Chief Legal Officer